Compare LESL & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LESL | NCEL |
|---|---|---|
| Founded | 1963 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | 4 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 20.6M |
| IPO Year | 2020 | N/A |
| Metric | LESL | NCEL |
|---|---|---|
| Price | $4.63 | $3.01 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $2.54 | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 26.1K |
| Earning Date | 05-18-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,241,915,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $1.83 |
| 52 Week High | $6.92 | $5.12 |
| Indicator | LESL | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 66.64 | 43.41 |
| Support Level | $3.50 | $2.50 |
| Resistance Level | $6.92 | $3.16 |
| Average True Range (ATR) | 0.65 | 0.27 |
| MACD | 0.15 | -0.04 |
| Stochastic Oscillator | 77.11 | 14.99 |
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products, including chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company serves residential pool, residential spa, professional pool, and commercial pool consumers and markets its products through over 1,000 company-operated locations in 39 states and e-commerce websites, operating only in the United States. It operates mainly in the pool and spa aftermarket industry and offers regularly purchased, non-discretionary maintenance items, along with installation and repair services for pool and spa equipment.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.